SCHEMBL8937540

SCHEMBL8937540

CCCOc1ccc(/C(=C\C(=O)N2CCN(C(=O)c3cc(OC)c(OC)c(OC)c3)CC2)c2cccc(C)c2)cc1OC

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.57
HSD17B10 Q99714 1/20 0.57
ALDH1A1 P00352 4/20 0.51
CYP1A2 P05177 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
LMNA P02545 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
HTT P42858 1/20 0.47
KDM4E B2RXH2 1/20 0.47
NPSR1 Q6W5P4 1/20 0.46
POLB P06746 2/20 0.46
CYP2C19 P33261 1/20 0.46
GPR183 P32249 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937319 1.00 HPGD (0.57) HPGDHSD17B10ALDH1A1CYP1A2L3MBTL1
SCHEMBL8937322 1.00 HPGD (0.57) HPGDHSD17B10ALDH1A1CYP1A2L3MBTL1
SCHEMBL8937360 0.92 ALDH1A1 (0.52) HPGDHSD17B10ALDH1A1CYP1A2L3MBTL1
SCHEMBL8937357 0.92 ALDH1A1 (0.52) HPGDHSD17B10ALDH1A1CYP1A2L3MBTL1
SCHEMBL8937601 0.92 HPGD (0.60) HPGDHSD17B10ALDH1A1CYP1A2L3MBTL1
SCHEMBL8937598 0.92 HPGD (0.60) HPGDHSD17B10ALDH1A1CYP1A2L3MBTL1
SCHEMBL8937575 0.91 ALDH1A1 (0.59) ALDH1A1CYP1A2L3MBTL1LMNASMN1; SMN2
SCHEMBL8937492 0.91 ALDH1A1 (0.59) ALDH1A1CYP1A2L3MBTL1LMNASMN1; SMN2
SCHEMBL8937495 0.91 ALDH1A1 (0.59) ALDH1A1CYP1A2L3MBTL1LMNASMN1; SMN2
SCHEMBL8937783 0.90 HPGD (0.56) HPGDHSD17B10ALDH1A1CYP1A2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 EP disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed
EP-0395446-A2 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists Sankyo Company Limited (JP) 1990-10-31 EP disclosed